PL1622648T3 - Szczepionki DNA przeciwko wzrostowi nowotworów i sposoby ich stosowania - Google Patents

Szczepionki DNA przeciwko wzrostowi nowotworów i sposoby ich stosowania

Info

Publication number
PL1622648T3
PL1622648T3 PL04749425T PL04749425T PL1622648T3 PL 1622648 T3 PL1622648 T3 PL 1622648T3 PL 04749425 T PL04749425 T PL 04749425T PL 04749425 T PL04749425 T PL 04749425T PL 1622648 T3 PL1622648 T3 PL 1622648T3
Authority
PL
Poland
Prior art keywords
human
protein
tumor growth
cancer
apoptosis
Prior art date
Application number
PL04749425T
Other languages
English (en)
Inventor
Rong Xiang
He Zhou
Ralph A Reisfeld
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of PL1622648T3 publication Critical patent/PL1622648T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
PL04749425T 2003-03-24 2004-03-24 Szczepionki DNA przeciwko wzrostowi nowotworów i sposoby ich stosowania PL1622648T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45700903P 2003-03-24 2003-03-24
PCT/US2004/008932 WO2004099389A2 (en) 2003-03-24 2004-03-24 Dna vaccines against tumor growth and methods of use thereof
EP04749425A EP1622648B1 (en) 2003-03-24 2004-03-24 Dna vaccines against tumor growth and methods of use thereof

Publications (1)

Publication Number Publication Date
PL1622648T3 true PL1622648T3 (pl) 2010-11-30

Family

ID=33434911

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04749425T PL1622648T3 (pl) 2003-03-24 2004-03-24 Szczepionki DNA przeciwko wzrostowi nowotworów i sposoby ich stosowania

Country Status (18)

Country Link
US (2) US8716254B2 (pl)
EP (1) EP1622648B1 (pl)
JP (1) JP4616827B2 (pl)
KR (1) KR101199789B1 (pl)
CN (1) CN1791433B (pl)
AT (1) ATE472339T1 (pl)
AU (1) AU2004236636B2 (pl)
BR (1) BRPI0408774A (pl)
CA (1) CA2519953C (pl)
DE (1) DE602004027902D1 (pl)
DK (1) DK1622648T3 (pl)
ES (1) ES2345200T3 (pl)
MX (1) MXPA05010255A (pl)
PL (1) PL1622648T3 (pl)
PT (1) PT1622648E (pl)
RU (1) RU2343195C2 (pl)
WO (1) WO2004099389A2 (pl)
ZA (1) ZA200508579B (pl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE026644T2 (en) 2004-05-28 2016-07-28 Oryxe A mixture for transdermal delivery of low and high molecular weight compounds
US20060276423A1 (en) * 2005-04-18 2006-12-07 Rachel Altura Survivin-directed RNA interference-compositions and methods
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
KR100790377B1 (ko) * 2006-02-15 2008-01-02 고려대학교 산학협력단 인터페론감마를 발현하는 살모넬라 균주를 함유하는항바이러스용 조성물
PT2035581E (pt) * 2006-06-21 2012-12-06 Scripps Research Inst Composição de adn contra o antigénio do estroma tumoral fap e métodos de utilização desta
JP2009542592A (ja) * 2006-07-06 2009-12-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Il−2媒介性免疫応答の有効性を高める組成物および方法
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
CA2670790A1 (en) * 2006-11-28 2008-06-05 Ghc Research Development Corporation Polypeptides comprising fas activation and nkg2d-ligand domains
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
AU2009232774B2 (en) * 2008-03-31 2014-05-29 Tella Inc. Partial peptide of Survivin presented on MHC class II molecule and use thereof
CN102365359B (zh) * 2009-03-27 2014-10-29 瑞士联邦苏黎世技术大学 呈递空肠弯曲杆菌n-聚糖或其衍生物的肠沙门氏菌
RU2431669C2 (ru) * 2009-06-23 2011-10-20 Государственное образовательное учреждение высшего профессионального образования "Казанский государственный университет им. В.И. Ульянова-Ленина" Способ получения лекарственного препарата генетически модифицированных клеток
US20120148581A1 (en) * 2009-08-17 2012-06-14 The Regents Of The University Of California Use of nkg2d inhibitors for treating cardiovascular and metabolic diseases, such as type 2 diabetes
KR101815322B1 (ko) * 2010-01-12 2018-01-05 서울대학교산학협력단 항암 펩타이드 서열
WO2011161244A1 (en) * 2010-06-25 2011-12-29 Vaccibody As Homodimeric protein constructs
CN102210862B (zh) * 2011-06-01 2013-06-12 中国人民解放军南京军区福州总医院 基于Livin的免疫刺激复合物及其制备方法和应用
IL298125A (en) * 2013-02-26 2023-01-01 Memorial Sloan Kettering Cancer Center Preparations and methods for immunotherapy
MX428954B (es) * 2013-03-15 2025-11-13 Univ Pennsylvania Vacunación mejorada contra la hormona liberadora de la hormona de crecimiento (ghrh) humana.
EP2981284A1 (en) * 2013-04-05 2016-02-10 Kyushu University National University Corporation Anti-tumor dna vaccine
WO2015001082A1 (en) * 2013-07-05 2015-01-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
EP3116903A2 (en) * 2014-03-14 2017-01-18 Dana-Farber Cancer Institute, Inc. Vaccine compositions and methods for restoring nkg2d pathway function against cancers
US10329552B2 (en) * 2014-08-29 2019-06-25 The Regents Of The University Of California Vaccine for livestock production systems
WO2016179573A1 (en) * 2015-05-07 2016-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Variant survivin vaccine for treatment of cancer
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3349717A4 (en) 2015-09-17 2019-04-17 JRX Biotechnology, Inc. APPROACHES TO IMPROVE SKIN HYDROGENATION OR HUMIDIFICATION
PT3356413T (pt) 2015-10-01 2022-04-04 Potenza Therapeutics Inc Proteínas de ligação a antigénio anti-tigit e métodos de utilização das mesmas
WO2018147801A1 (en) * 2017-02-07 2018-08-16 Agency For Science, Technology And Research Methods and kits for generating mimetic innate immune cells from pluripotent stem cells
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
CN110448689A (zh) * 2019-08-06 2019-11-15 太仓美诺恒康生物技术有限公司 mRNA疫苗及其试剂盒、应用
CN114867490A (zh) * 2019-09-20 2022-08-05 克莱格医学有限公司 细胞因子调控表达的免疫效应细胞
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
AU2022208435A1 (en) 2021-01-18 2023-08-10 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
RU2770490C1 (ru) * 2021-07-14 2022-04-18 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр "Красноярский научный центр Сибирского отделения Российской академии наук" Рекомбинантная плазмидная ДНК pET19b-Surv-OL, обеспечивающая синтез гибридного белка сурвивин-обелин (Surv-OL) и гибридный белок, связываемый анти-сурвивин антителами и обладающий биолюминесцентной активностью
CN116077534B (zh) * 2023-01-31 2024-08-27 大连工业大学 一种凝结芽孢杆菌的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993223A (en) * 1974-07-25 1976-11-23 American Home Products Corporation Dispensing container
GB9104596D0 (en) * 1991-03-05 1991-04-17 Wellcome Found Production of recombinant proteins
US5702917A (en) * 1992-01-27 1997-12-30 Icos Corporation Polynucleotides encoding human ICAM-4
RU2077340C1 (ru) * 1993-08-06 1997-04-20 Всероссийский научно-исследовательский институт ветеринарной вирусологии и микробиологии Способ получения специфической сыворотки для лечения, диагностики и профилактики вирусной геморрагической болезни кроликов и набор для диагностики болезни
US5733760A (en) * 1994-08-05 1998-03-31 Virus Research Institute Salmonella vectors encoding truncated pag fusion protein, method of making, and uses thereof
US6190657B1 (en) * 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
RU2219942C2 (ru) * 1996-02-24 2003-12-27 Берингер Ингельхайм Интернациональ Гмбх Лекарственный состав с иммуномодуляторным действием, содержащий пептиды и вспомогательные средства
DE69739105D1 (de) * 1996-11-20 2008-12-24 Univ Yale Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation
ATE421888T1 (de) * 1997-08-13 2009-02-15 Uab Research Foundation Impfung durch topische verwendung genetischer vektoren
WO1999031241A1 (en) * 1997-12-17 1999-06-24 Immunex Corporation Cell surface glycoproteins associated with human b cell lymphomas - ulbp, dna and polypeptides
US20030215803A1 (en) * 2000-12-07 2003-11-20 Garcia Pablo Dominguez Human genes and gene expression products isolated from human prostate
AU4990999A (en) * 1998-07-14 2000-02-07 Jenner Biotherapies, Inc. Survivin, and peptides thereof, as an anti-cancer vaccine
US6472172B1 (en) * 1998-07-31 2002-10-29 Schering Aktiengesellschaft DNA encoding a novel human inhibitor-of-apoptosis protein
US6838283B2 (en) * 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
IT1303683B1 (it) * 1998-10-30 2001-02-23 Menarini Ricerche Spa Composizione farmaceutiche ad azione antitumorale contenente dnacodificante per frammenti di una proteina antigenica.
US6413768B1 (en) * 1998-12-02 2002-07-02 University Of Maryland Expression plasmids
ATE279125T1 (de) * 1998-12-18 2004-10-15 Symrise Gmbh & Co Kg Eingekapselte aroma- und/oder riechstoffzubereitungen
WO2002002622A2 (en) * 2000-06-29 2002-01-10 The Salk Institute For Biological Studies Crystal structure of survivin
EP1256354A1 (en) * 2001-05-11 2002-11-13 Schering Corporation Methods for treating cancer
AU2002326961A1 (en) * 2001-10-10 2003-04-22 Centocor, Inc. Nucleic acid vaccines using tumor antigen encoding nucleic acids with cytokine adjuvant encoding nucleic acid
CA2500661A1 (en) * 2002-10-01 2004-04-15 Chiron Corporation Anti-cancer and anti-infectious disease compositions and methods for using same
US20040224408A1 (en) * 2002-12-10 2004-11-11 Jean-Philippe Girard THAP proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation

Also Published As

Publication number Publication date
KR20050121694A (ko) 2005-12-27
RU2343195C2 (ru) 2009-01-10
EP1622648A2 (en) 2006-02-08
AU2004236636B2 (en) 2010-02-04
JP2006523217A (ja) 2006-10-12
EP1622648A4 (en) 2007-02-14
CN1791433A (zh) 2006-06-21
JP4616827B2 (ja) 2011-01-19
PT1622648E (pt) 2010-08-31
US8716254B2 (en) 2014-05-06
AU2004236636A1 (en) 2004-11-18
KR101199789B1 (ko) 2012-11-09
DK1622648T3 (da) 2010-09-06
ZA200508579B (en) 2007-04-25
RU2005132578A (ru) 2006-05-10
CN1791433B (zh) 2010-05-26
WO2004099389A2 (en) 2004-11-18
MXPA05010255A (es) 2005-12-14
US20040192631A1 (en) 2004-09-30
BRPI0408774A (pt) 2006-03-28
EP1622648B1 (en) 2010-06-30
ATE472339T1 (de) 2010-07-15
ES2345200T3 (es) 2010-09-17
DE602004027902D1 (de) 2010-08-12
US20140322249A1 (en) 2014-10-30
CA2519953A1 (en) 2004-11-18
WO2004099389A3 (en) 2005-09-29
US9655815B2 (en) 2017-05-23
CA2519953C (en) 2016-01-05

Similar Documents

Publication Publication Date Title
MXPA05010255A (es) Vacunas de adn contra crecimiento tumoral y metodos de uso de las mismas.
Li et al. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself
Moschella et al. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients
McLaughlin et al. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2
CA2267157A1 (en) Cancer immunotherapy using tumor cells combined with mixed lymphocytes
ATE272407T1 (de) Spezifische krebs-immuntherapie mit rekombinantem bakteriellem impfstoff
EP3456350B1 (en) Aluminum hydroxide gel-sodium chloride composite immunologic adjuvant, and preparation method therefor and application thereof
EP2752193B1 (en) Allogeneic cancer cell-based immunotherapy
Ding et al. Coadministration of the fungal immunomodulatory protein FIP‐Fve and a tumour‐associated antigen enhanced antitumour immunity
Kao et al. Superior efficacy of dendritic cell-tumor fusion vaccine compared with tumor lysate-pulsed dendritic cell vaccine in colon cancer
Tseng et al. Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination
WO2004027036A3 (en) Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine
Tewari et al. Dendritic cell therapy in advanced gastric cancer: a promising new hope?
Kim et al. Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination
CN101072582B (zh) 作为癌症疫苗佐剂的α胸腺肽
Behboudi et al. Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction
Shafer-Weaver et al. T cell tolerance to tumors and cancer immunotherapy
Yang et al. Dendritic cells pulsed with GST–EGFR fusion protein: Effect in antitumor immunity against head and neck squamous cell carcinoma
Naylor et al. IRX-2 increases the T cell-specific immune response to protein/peptide vaccines
Osman et al. Generation of Ag-specific cytotoxic T lymphocytes by DC transfected with in vitro transcribed influenza virus matrix protein (M1) mRNA
Schirrmacher T cell-mediated immunotherapy of metastases: state of the art in 2005
Peng et al. Induction of cytotoxic T-lymphocyte responses using dendritic cells transfected with hepatocellular carcinoma mRNA
Schabowsky et al. ProtEx™ technology for the generation of novel therapeutic cancer vaccines
Kabaker et al. Vaccines for colorectal cancer and renal cell carcinoma
Shinde et al. Understanding how combinatorial targeting of TLRs and TNFR family costimulatory members promote enhanced T cell responses